Clinical

Dataset Information

0

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)


ABSTRACT: This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as first-line therapy of patients with KRAS wild-type metastatic colorectal cancer. Only subjects with k-ras oncogene (KRAS) wild-type tumors are eligible. Efficacy will be assessed every 8 weeks. Treatment will be continued until progressive disease or unacceptable adverse events occur. After the end of study treatment, information on further anticancer treatment and survival will be collected every 3 months.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2063032 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2037434 | ecrin-mdr-crc
| 2129434 | ecrin-mdr-crc
2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress
| EGAS00001001745 | EGA
| EGAS00001001743 | EGA
| EGAS00001001744 | EGA
2014-04-01 | E-GEOD-56386 | biostudies-arrayexpress
2012-01-01 | E-GEOD-32048 | biostudies-arrayexpress
2007-09-12 | GSE8967 | GEO
2012-01-01 | GSE32048 | GEO